Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells

查看全文 作　　者：Ying [1,5]Qiu;Ming-Bao [2]Xu;Mark M [3]Yun;Yi-Zhong [4]Wang;Rui-Ming [1]Zhang;Xing-Kai [1]Meng;Xiao-[1]Hui;Ou-[1]Yang;Sheng [1,4,6]Yun

机构地区：[1]The First Teaching Hospital, Inner Mongolia Medical College, Huhhot 010050, Inner Mongolia Autonomous Region, China;[2]The Armed Police General Hospital, Beijing100036, China;[3]Medical School of UCL, London WC1E 6BT,United Kingdom;[4]Aerospace Medical College, Peking University, Beijing 100049, China;[5]Department of Clinical Sciences, King's College Hospital, London SE5 9NU, United Kingdom;[6]Clinical Sciences Centre, MRC, HammersmithHospital Campus, London W12 0NN, United Kingdom

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第48期,共7页

基　　金：Supported by Hong Kong Wang Kuan Cheng Grant;Inner Mongolia Stem Cell Grant, No. kjk10jhg 摘　　要：AIM: To evaluate the safety and clinical efficacy of a new immunotherapy using both α-Gal epitope-pulsed dendritic cells (DCs) and cytokine-induced killer cells.METHODS: Freshly collected hepatocellular carcinoma(HCC) tumor tissues were incubated with a mixture of neuraminidase and recombinant α1,3-galactosyltransferase (α1,3GT) to synthesize α-Gal epitopes on carbohydrate chains of the glycoproteins of tumor membranes. The subsequent incubation of the processed membranes in the presence of human natural anti-Gal IgG resulted in the effective phagocytosis to the tumor membrane by DCs. Eighteen patients aged 38-78 years with stage Ⅲ primary HCC were randomLy chosen for the study; 9 patients served as controls, and 9 patients were enrolled in the study group.RESULTS: The evaluation demonstrated that the procedure was safe; no serious side effects or autoimmune diseases were observed. The therapy significantly prolonged the survival of treated patients as compared with the controls (17.1 ± 2.01 mo vs 10.1 ± 4.5 mo,P = 0.00121). After treatment, all patients in the study group had positive delayed hyper sensitivity and robust systemic cytotoxicity in response to tumor lysate as measured by interferon-γ-expression in peripheral blood mononuclear cells using enzyme-linked immunosorbent spot assay. They also displayed increased numbers of CD8-, CD45RO-and CD56-positive cells in the peripheral blood and decreased α-fetoprotein level in the serum.CONCLUSION: This new tumor-specific immunotherapy is safe, effective and has a great potential for the treatment of tumors. 关键词：Hepatocellular carcinoma α-Gal epitope Dendritic cell Tumor-associated antigen Dendritic cell-activated cytokine-induced killer cell

相关文献

参考文献（26）
引证文献（8）
耦合文献（102）

参考文献(26)

引证文献(8)

耦合文献(102)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3-galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cells

参考文献(26)

引证文献(8)

耦合文献(102)

用户提示